Journal of Neural Transmission

Article	Citations
Facets of movement disorders– a tribute to Heinz Reichmann	127
Current perspectives on brain circuits involved in food addiction-like behaviors	84
Alterations in metabolites in the anterior cingulate cortex and thalamus and their associations with pain and empathy in patients with chronic mild pain: a preliminary study	83
Neuromodulation of excitation-inhibition balance in dementia with lewy bodies: a translational framework	77
Celebrating the career of professor Zdravko Lacković: a life in neuroscience, pharmacology, and discovery	70
Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer’s disease: long-term follow up	69
Dopamine agonists in the treatment of Parkinson's disease: the show must go on	68
A kynurenine pathway enzyme aminocarboxymuconate-semialdehyde decarboxylase may be involved in treatment-resistant depression, and baseline inflammation status of patients predicts treatment response:	65
Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson’s disease	59
Do demographic and clinical features and comorbidities affect the risk of spread to an additional body site in functional motor disorders?	54
Neuromelanin granules of the substantia nigra: proteomic profile provides links to tyrosine hydroxylase, stress granules and lysosomes	54
Contrasting features between Tourette syndrome and secondary tic disorders	51
Sitagliptin attenuates L-dopa-induced dyskinesia by regulating mitochondrial proteins and neuronal activity in a 6-OHDA-induced mouse model of Parkinson’s disease	51
A wearable device-enabled therapeutic approach to improve joint attention in autism spectrum disorder: a prospective pilot study	50
Pathogenesis of Parkinson’s disease: from hints from monogenic familial PD to biomarkers	47
EEG power spectral and microstate analyses in the 22q11.2 deletion syndrome: from genetic risk to schizophrenia	43
Movement disorders associated with diarrhoea	42
Stress enhances heartbeat-evoked potentials, independent of continuous or intermittent theta burst stimulation of the interoceptive brain network targeting the right supramarginal gyrus: a preliminary	39
Eye movement study in essential tremor patients and its clinical correlates	39
The pathobiology of depression in Huntington’s disease: an unresolved puzzle	36
Comparison of inflammatory biomarker levels in neurodegenerative proteinopathies: a case-control study	35
The role of immune and inflammatory-related indicators in cognitive dysfunction and disease severity in patients with parkinson’s disease	34
Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016	32
Unravelling head tremor mechanisms: insights from speech analysis in essential tremor and cervical dystonia	32
Understanding cognitive features of cervical dystonia: application of the cerebellar cognitive affective syndrome scale (CCAS-S)	31

Non motor Parkinson: subtypes, biomarkers, stepped care and a journal!	31
Botulinum toxin and conservative treatment strategies in people with cervical dystonia: an online survey	31
Unusual delayed and prolonged arm weakness and atrophy following botulinum toxin injection for musician’s cramp: case report	29
Botulinum toxin effects on biochemical biomarkers related to inflammation-associated head and neck chronic conditions: a systematic review of clinical research	29
Association between autonomic dysfunction with motor and non-motor symptoms in patients with Parkinson's disease	28
The spectrum of behavioral disorders in amyotrophic lateral sclerosis: current view	26
Bradykinesia and rigidity modulated by functional connectivity between the primary motor cortex and globus pallidus in Parkinson’s disease	26
Camillo Golgi’s contributions to the anatomic basis of sensitivity in tendons	24
COMT inhibition with entacapone for patients with Parkinson’s disease and motor complications: the novelty of continuous infusion	23
Axial postural abnormalities and pain in Parkinson’s disease	23
The potential role of kynurenine pathway and inflammation in pediatric obsessive-compulsive disorder with and without major depressive disorder comorbidity	23
Botulinum toxin for chronic migraine	23
Effectiveness, safety, and quality of life outcomes of neurotoxin injections in the treatment of essential tremors: a systematic review	23
Impact of APOE and MAPT genetic profile on the cognitive functions among Amyotrophic Lateral Sclerosis Tunisian patients	22
The corticospinal tract in multiple sclerosis: correlation between cortical excitability and magnetic resonance imaging measures	21
Cerebral glucose metabolism: the potential missing link in autism research—a literature review and meta-analytic synthesis	21
Obesity-related RNA m6A demethylase gene FTO rs1421085 is associated with neuroticism in a longitudinal birth cohort study	21
Constipation and pain in Parkinson’s disease: a clinical analysis	21
A call to action: revitalizing the German parkinson’s research ecosystem post-pandemic	21
Ischemic stroke and transient ischemic attack associated with neuroborreliosis: a Danish retrospective cohort	20
Old problems, new solutions: harnessing technology and innovation in Parkinson’s disease—evidence and experiences from Thailand	20
MeDeMSA care study protocol: developing personalized best medical care with integrated mobile palliative and telemedicine support for individuals with multiple system atrophy	19
Influence of the level of education on cognitive function in Parkinson’s disease	19
Regulation of circadian gene activity in fibroblasts from ADHD patients through Rosiglitazone: a pilot study	18
Chronic exposure to a synthetic cannabinoid alters cerebral brain metabolism and causes long-lasting behavioral deficits in adult mice	18
The relationship of early life adversity and physiological synchrony within the therapeutic triad in horse-assisted therapy	18
Caregiver burden of parkinsonian patients with impulse control disorders, depression and apathy	18
Illness perceptions in pre-operative Parkinson’s disease patients	18
Toward preventive interventions in developmental coordination disorder: in need of early behavioral markers?	18
Insulin resistance: fueling oxidative stress and neurodegeneration	18
Inhaled levodopa for threatening impending OFF episodes in managing Parkinson’s disease	18
Potentially inappropriate medications according to PRISCUS list and FORTA (Fit fOR The Aged) classification in geriatric psychiatry: a cross-sectional study	17
The brainstem reticular formation pivots abnormal neural transmission in the course of Anorexia Nervosa	17
Advanced therapy in advanced Parkinson’s disease: money’s too tight to mention	17
Prenatal exposure to morphine enhances excitability in locus coeruleus neurons	17
Linking diet, gut microbiota, and metabolites to Parkinson’s disease risk: a shotgun metagenomic comparison of Japanese and Taiwanese cohorts	17
Pharmacogenetics in advanced Parkinson’s disease	16
Update on sleep disorders in advanced Parkinson’s disease: a narrative review	16
Is there a link between multiple sclerosis and Alzheimer disease? A critical note	16
In situ stoichiometry amounts of p62 and poly-ubiquitin exceed the increase of alpha-synuclein during degeneration of catecholamine cells induced by autophagy inhibition in vitro	16
The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone	15
Drug repurposing and new drug targets: perspectives for novel treatment options in mental health disorders	15
The two-network framework of number processing: a step towards a better understanding of the neural origins of developmental dyscalculia	15
Neuroscience and addiction research: current advances and perspectives	15
Retraction Note: Expression of heat shock protein (HSP 72 kDa) during acute methamphetamine intoxication depends on brain hyperthermia: neurotoxicity or neuroprotection?	15
Psychological, neuroendocrine and inflammatory stress responses in women after miscarriage or stillbirth: investigating early psychobiological adaptations to potential traumatic events	15
MAOA methylation is associated with impulsive and antisocial behaviour: dependence on allelic variation, family environment and diet	14
Type A monoamine oxidase; its unique role in mood, behavior and neurodegeneration	14
Effects of association between resveratrol and ketamine on behavioral and biochemical analysis in mice	14
Autism Spectrum Disorder and auditory sensory alterations: a systematic review on the integrity of cognitive and neuronal functions related to auditory processing	14

Serum glial fibrillary acidic protein is elevated in early-stage late-onset essential tremor and associated with tremor progression	14
Sleep disorders among frontline nurses after the COVID-19 outbreak: a large-scale cross-sectional study	14
Language in autism: domains, profiles and co-occurring conditions	14
The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment	13
The natural course of idiopathic cervical dystonia	13
Characteristics of behavioural addiction in Parkinson’s disease patients with self-reported impulse control disorder and controls matched for levodopa equivalent dose: a matched case–control study	13
Atrophy of cerebellar lobule VI and primary motor cortex in cervical dystonia - a region of interest-based study	13
Exploring developmental trajectories throughout adolescence of children with autism spectrum disorder without intellectual disability	13
Sexual dysfunction in men with young onset Parkinson's disease	13
Resting-state EEG changes associated with cognitive decline in Parkinson’s disease: a systematic review	13
Issues for patchy tissues: defining roles for gut-associated lymphoid tissue in neurodevelopment and disease	13
Exploring transferability in psychiatric interventions: a conceptual framework	13
Psychosis in Huntington disease: a short update	13
Reduced cerebrospinal fluid taurine is associated with nigrostriatal dopaminergic deficits in drug-naïve Parkinson’s disease	13
Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide	12
Transcriptional dysregulation in the cerebellum triggered by oligodendroglial α-synucleinopathy: insights from a transgenic mouse into the early disease mechanisms of MSA	12
Investigation of the nonmotor symptoms in patients with STN-DBS therapy in comparison with those without STN-DBS	12
Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?	12
Clinimetrics of the Italian version of the Montreal Cognitive Assessment (MoCA) in adult-onset idiopathic focal dystonia	12
Impact of device-aided therapies on quality of life in patients with Parkinson’s disease. A comparative multicenter observational study	12
Tips and tricks in tremor treatment	12
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease	12
Perceived social support declines after deep brain stimulation surgery in patients with Parkinson’s disease	12
Parkinson’s disease, aerobic exercise and photobiomodulation: a randomised controlled trial	12
Pesticides and parkinson’s disease: causal relationship at the population and individual level?	12
Developing Botulinum Toxin Drugs: Unexpected Challenges	12
The vicious circle between homocysteine, methyl group-donating vitamins and chronic levodopa intake in Parkinson’s disease	12
Oligodendrocytes matter: a review of animal studies on early adversity	12
Therapeutic use of medical Cannabis in neurological diseases: a clinical update	11
Cognitive impairment in Parkinson’s disease and other parkinsonian syndromes	11
Maternal separation and its developmental consequences on anxiety and parvalbumin interneurons in the amygdala	11
High-dose glucocorticoids in COVID-19 patients with acute encephalopathy: clinical and imaging findings in a retrospective cohort study	11
RNA sequencing of the thalamus and rostral ventral medulla in rats with chronic orofacial pain	11
The prevalence of gastrointestinal dysfunction and its impact on quality of life in Parkinson’s disease	11
Memantine: updates from the past decade and implications for future novel therapeutic applications	11
Unraveling mGluR5 dysfunction in autism spectrum disorder: a multi-level analysis of genetic, molecular, and neurobiological mechanisms	11
Posttraumatic growth and wellbeing in three countries after COVID-19: analysis using a random intercept cross-lagged panel model	11
Usability of the digit-tracking technique in a geriatric population of inpatients with and without neurocognitive disorders: The DIGICOG-start study	11
Patterns of striatal dopamine depletion and motor deficits in de novo Parkinson’s disease	11
Writing tremor in Parkinson’s disease: frequency and associated clinical features	11
Unveiling the link between chronic pain and misuse of opioids and cannabis	11
If you can't be with the one you love, love the one you're with (C, S, N & Y)	11
EEG neurosubtyping of infants predicts language trajectories	11
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A	10
Plasma prolactin and symptoms of schizophrenia	10
Mild cognitive impairment in amyotrophic lateral sclerosis: current view	10
Real-world experience with continuous subcutaneous foslevodopa/foscarbidopa infusion: insights and recommendations	10
Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook	10
Neuromarkers in addiction: definitions, development strategies, and recent advances	10
How to treat cardiovascular autonomic failure in Parkinson’s disease	10
Botulinum toxin treatment for hemifacial spasm: harmonising neurological and aesthetic outcomes	10
Myopathies in clinical care: a focus on treatable causes	10
The pathobiological basis of depression in Parkinson disease: challenges and outlooks	9
The brain and heart-axis in neurodegeneration and cardiovascular disease	9
Environmental opportunities facilitating cognitive development in preschoolers: development of a multicriteria index	9
A smartphone-based tapping task as a marker of medication response in Parkinson’s disease: a proof of concept study	9
Motor and non-motor improvements following short-term multidisciplinary day-clinic care in Parkinson´s disease	9
The relationship between serum prolactin levels and cognitive function in drug-naïve schizophrenia patients: a cross-sectional study	9
The akinetic crisis in Parkinson´s disease- the upper end of a spectrum of subacute akinetic states	9
Neuropathology in genetic Parkinson’s disease: a focused review of pathological and clinical findings	9
The effect of recombinant botulinum neurotoxin A on neuropathic pain in the spared nerve injury mouse model	9
Depression in dementia with Lewy bodies: a critical update	9
Advanced is advanced is advanced is advanced	9
HDL cholesterol indicates neurodegenerative vulnerability in dementia with lewy bodies	9
Correction: The neural structures of theory of mind are valence-sensitive: evidence from three tDCS studies	9
Mild cognitive impairment in Huntington’s disease: challenges and outlooks	9
Altered platelet function in persistent depressive disorder: a study of density subpopulations and fibrinogen binding	9
Correlation between the MNCD classification-based staging of Parkinson’s disease and quality of life: a cross-sectional study	9
Depression and anxiety in multiple sclerosis. Review of a fatal combination	9
Psychotherapies in opioid use disorder: toward a step-care model	9
Cognitive reappraisal training as an intervention in patients with functional movement disorders: a placebo-controlled EEG pilot study	9
Catecholamines and Parkinson’s disease: tyrosine hydroxylase (TH) over tetrahydrobiopterin (BH4) and GTP cyclohydrolase I (GCH1) to cytokines, neuromelanin, and gene therapy: a historical overview	9
Differential diagnosis of Huntington’s disease− neurological aspects of NKX2-1-related disorders	9
Mediating roles of attention-deficit/hyperactivity disorder symptom severity and self-control on the relationship between adverse childhood experiences and adult aggression	9
Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson's syndrome	8
Mild cognitive impairment in multiple system atrophy: a brain network disorder	8
Facial emotion recognition deficits are associated with hypomimia and related brain correlates in Parkinson’s disease	8
The heterogeneity of Parkinson’s disease	8
Nonmotor symptoms of craniocervical dystonia: a multicentre international study—using the Dystonia nonmotor symptoms questionnaire	8
Manufacture of the first FDA-approved batches of 900 kilodalton crystalline type a botulinum toxin for clinical use: a personal remembrance	8

The sex-specific relationship of ghrelin and cognition in Chinese han first-episode drug-naive major depressive disorder	8
From parents to children: associations of traffic risks with impulsivity, family relationships and serotonin transporter genotype	8
The efficacy of acoustic-based articulatory phenotyping for characterizing and classifying four divergent neurodegenerative diseases using sequential motion rates	8
A narrative review of clinical and non-clinical determinants of health-related quality of life in advanced Parkinson’s disease	8
Iron and copper ions accelerate and modify dopamine oxidation to eumelanin: implications for neuromelanin genesis	8
The mouse diaphragm assay in botulinum toxin therapy	7
Lifestyle medicine in Parkinson’s disease	7
The impact of short-term blood pressure variability on cognitive decline in Parkinson’s disease patients without co-morbidities	7
Driving innovation in addiction treatment: role of transcranial magnetic stimulation	7
Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease	7
Genes critical for development and differentiation of dopaminergic neurons are downregulated in Parkinson’s disease	7
Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications	7
Deep brain stimulation in progressive supranuclear palsy: a dead-end story? A narrative review	7
GBA-associated PD: chances and obstacles for targeted treatment strategies	7
Nicotinic regulation of microglia: potential contributions to addiction	7
Repurposing drugs against Alzheimer’s disease: can the anti-multiple sclerosis drug fingolimod (FTY720) effectively tackle inflammation processes in AD?	7
Clinical utility of digital technologies in Parkinson’s disease	7
Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?	7
Cognition and Activity of Daily Living Function in people with Parkinson’s disease	7
Drug interactions in a sample of inpatients diagnosed with cannabis use disorder	7
Neurogenic orthostatic hypotension in Parkinson’s disease: is there a role for locus coeruleus magnetic resonance imaging?	7
New trends in the research of psychiatric and neurodegenerative diseases: a tribute to Melita Salkovic-Petrisic	7
Identification of DAGLB variants in Japanese early-onset Parkinson’s disease	7
Methods to detect anxiety in Parkinsons’ disease	7
Bioinformatics approach reveals the critical role of the NOD-like receptor signaling pathway in COVID-19-associated multiple sclerosis syndrome	7
Tools and criteria to select patients with advanced Parkinson’s disease for device-aided therapies: a narrative review	7
Genetic and environmental mouse models of autism reproduce the spectrum of the disease	7
A structured framework for emotion-cognition dynamics: Implications for assessment and intervention	7
Interrater reliability of motor severity scales for hemifacial spasm	7
Plasma concentrations of anti-inflammatory cytokine TGF-β are associated with hippocampal structure related to explicit memory performance in older adults	7
Insights into insulin signalling and oxidative stress in the Tg2576 mouse model of familial Alzheimer’s disease: effects of chronic oral galactose administration	7
Association between alcohol consumption and mortality in Parkinson’s disease	7
Sodium valproate and gabapentin reduce the seizure-like behavior induced by pentylenetetrazol and mechanical stress in Drosophila melanogaster: sex influence on behavioral responses	7
Probing the properties of PTEN specific botulinum toxin type E mutants	7
Concomitant pathologies and their impact on Huntington’s disease. A brief review of current evidence	7